Posted in | News | Microscopy

Bruker Announces Acquisition of High-Speed, 3D Super-Resolution Fluorescence Microscopy Company Vutara

Bruker announced that it has acquired Vutara Incorporated, a technology leader in high-speed, three-dimensional (3D), super-resolution fluorescence microscopy for life science applications. Transaction details were not disclosed. Vutara’s estimated revenue for the full year 2014 is expected to be approximately $2 million.

The acquisition further strengthens Bruker’s biological microscopy business by adding super-resolution and single-molecule localization (SML) microscopy products to Bruker’s existing portfolio of multi-photon and fast, multi-point scanning confocal fluorescence microscopes, as well as of high-performance atomic force microscopes. Super-resolution microscopes can break the optical diffraction limit by an order of magnitude, opening up a myriad of research opportunities in single-molecule, cellular and neurobiology processes.

“Super-resolution microscopy is emerging as a critical requirement for our customers, and being able to integrate Vutara’s best-in-class high-speed, 3D super-resolution systems with our line of multi-photon and multi-point scanning optical microscopy technologies will provide a significant benefit to the research community,” said Mark R. Munch, Ph.D., President of the Bruker MAT Group. “Achieving video-rate time resolution, higher spatial resolution, all with improved ease of use, is generating considerable excitement in this rapidly growing area, and this is exactly what Vutara brings to Bruker’s customers with its proprietary technology.”

“Bruker’s prominence in life science research will further accelerate the adoption of our performance-leading super-resolution microscopes,” added Stan Kanarowski, CEO of Vutara, Inc. “Moreover, the combination of the Vutara and Bruker optical engineering and microscopy application experts is expected to lead to the development of a steady stream of additional innovative, high-impact products for cell and neurobiology research.”

“We have seen firsthand the benefits that Bruker’s global distribution and service capabilities can add to our advanced multi-photon portfolio,” explained Mike Szulczewski, Vice President and General Manager of the Bruker Fluorescence Microscopy business unit. “I am pleased to have Vutara’s fast, 3D super-resolution and SML technologies now added to our business, as this immediately broadens our high-performance product offerings. It also allows us to further develop our solutions for the next level of functionality and versatility, with unique combinations of resolution, speed, depth and ease of use on samples ranging from live cells to living brains.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bruker Nano Surfaces and Metrology. (2019, February 11). Bruker Announces Acquisition of High-Speed, 3D Super-Resolution Fluorescence Microscopy Company Vutara. AZoNano. Retrieved on December 11, 2024 from https://www.azonano.com/news.aspx?newsID=30830.

  • MLA

    Bruker Nano Surfaces and Metrology. "Bruker Announces Acquisition of High-Speed, 3D Super-Resolution Fluorescence Microscopy Company Vutara". AZoNano. 11 December 2024. <https://www.azonano.com/news.aspx?newsID=30830>.

  • Chicago

    Bruker Nano Surfaces and Metrology. "Bruker Announces Acquisition of High-Speed, 3D Super-Resolution Fluorescence Microscopy Company Vutara". AZoNano. https://www.azonano.com/news.aspx?newsID=30830. (accessed December 11, 2024).

  • Harvard

    Bruker Nano Surfaces and Metrology. 2019. Bruker Announces Acquisition of High-Speed, 3D Super-Resolution Fluorescence Microscopy Company Vutara. AZoNano, viewed 11 December 2024, https://www.azonano.com/news.aspx?newsID=30830.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.